Cingulate receives U.S. patent for CTx-2103 anxiety treatment formulation
CING•Cingulate received a U.S. patent covering its buspirone tablet formulation for CTx-2103, an anxiety treatment candidate. The formulation uses Precision Timed Release technology to deliver medication at three predetermined times throughout the day from one tablet.
1. Patent covers formulation
Cingulate received a U.S. patent covering its buspirone tablet formulation for CTx-2103, an anxiety treatment candidate. The formulation uses proprietary Precision Timed Release technology to deliver medication at three predetermined times throughout the day from one tablet.



